Source: International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Cadranel (Paris Cedex 20, France). Concomitant versus sequential third-generation targeted therapies in advanced epidermal growth factor receptor- or anaplastic lymphoma kinase-positive NSCLC. International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas

Member's Comments

No comment yet.

Related content which might interest you: Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 A rare choroidal metastasis in ALK+ non-small cell lung cancer (NSCLC) that responds to Crizotinib Source: International Congress 2019 – CCC Thoracic oncology Year: 2019 The response to erlotinib third-line treatment in bronchioalveolar carcinoma in the absence of EGFR expression Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Adenovirus-mediated interferon-beta gene therapy inhibits tumor growth and inhibits metastatic lung tumors in mice Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002